Wellington Management Group LLP Reduces Position in HealthEquity, Inc. $HQY
Wellington Management Group LLP has reduced its stake in HealthEquity, Inc. (NASDAQ:HQY) by 22% during the second quarter, selling 109,626 shares but still retaining 387,894 shares valued at approximately $35 million. Despite this reduction, institutional investors collectively own 99.55% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $111.87. HealthEquity has also reported strong quarterly earnings, exceeding expectations with adjusted EPS of $1.24 and a 95.5% year-over-year revenue increase.
HealthEquity (NASDAQ:HQY) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen downgraded HealthEquity (NASDAQ:HQY) from "Buy" to "Hold," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $111.87. HealthEquity's shares dropped 2.7% to $96.07, even after the company surpassed quarterly expectations with $1.24 EPS and $350.73 million in revenue. Insider selling of 12,456 shares worth $1.26 million was noted, while institutional investors hold 99.55% of the company.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) is a recommended hold due to its strong fiscal second-quarter 2027 performance and growth in Health Savings Accounts (HSAs), driven by AI and digital innovation. The company's adjusted EBITDA guidance was raised, and it reported significant increases in HSA assets and accounts. However, potential risks from data security threats and an ongoing class-action lawsuit are factors that could offset these gains.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock is recommended for holding due to its strong business model, impressive second-quarter fiscal 2027 performance, and robust Health Savings Accounts (HSAs) growth, driven by AI and digital innovation. Despite concerns about data security threats, the company has seen positive estimate revisions for fiscal 2027 and continues to expand its HSA offerings. Its financial results show increased revenues, improved margins, and a strengthened financial position.
Raymond James reiterates Strong Buy on HealthEquity stock after earnings beat
Raymond James has reiterated a Strong Buy rating and set a $115.00 price target for HealthEquity (NASDAQ:HQY) following the company's Q2 fiscal 2027 earnings beat. The firm expects healthcare affordability pressures and increasing member engagement to drive HealthEquity's account growth and monetization. HealthEquity also raised its full-year fiscal 2027 guidance for revenue, adjusted EBITDA, and GAAP earnings per share, with strong performance driven by new health savings account growth and operational efficiencies from AI automation.
Corient Private Wealth LP Buys New Position in HealthEquity, Inc. $HQY
Corient Private Wealth LP has acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY), purchasing 27,415 shares valued at approximately $2.48 million during the second quarter. HealthEquity reported strong quarterly earnings, surpassing analyst expectations with $1.24 EPS on $350.73 million in revenue, a 95.5% increase year-over-year. Analysts generally maintain a "Moderate Buy" rating for HQY, with an average price target of $111.87, despite recent insider share sales.
Raymond James reiterates Strong Buy on HealthEquity stock after earnings beat
Raymond James has reiterated a Strong Buy rating for HealthEquity (NASDAQ:HQY) and maintained a $115.00 price target after the company reported second-quarter fiscal 2027 results that surpassed consensus estimates for revenue, adjusted EBITDA margin, and adjusted earnings per share. The firm believes that healthcare affordability pressures and increasing member engagement will continue to drive the company's account growth and monetization. HealthEquity also raised its full-year fiscal 2027 guidance and is considered undervalued according to InvestingPro analysis, with a "GREAT" financial health score.
B. Metzler seel. Sohn & Co. AG Acquires 25,418 Shares of HealthEquity, Inc. $HQY
B. Metzler seel. Sohn & Co. AG increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 29.7% in the second quarter, now owning 111,108 shares valued at $10.0 million. This move comes as HealthEquity reported strong second-quarter earnings, exceeding analyst expectations with $1.24 EPS and $350.73 million in revenue, a 95.5% year-over-year increase. The company also issued positive fiscal 2027 EPS guidance, contributing to a "Moderate Buy" consensus rating from analysts with an average price target of $111.87.
HQY Up 15.7% in 3 Months as HSA Growth Builds: Can the Rally Continue?
HealthEquity (HQY) shares have risen 15.7% in the past three months due to strong growth in Health Savings Accounts (HSAs) and assets, better-than-expected fiscal second-quarter results, and expanded margins. Management has also raised fiscal 2027 revenue and adjusted EBITDA guidance. However, potential risks from cybersecurity litigation, regulatory inquiries, competitive pricing, and interest rate sensitivity suggest a balanced risk-reward outlook.
Two Sigma Securities LLC Takes Position in HealthEquity, Inc. $HQY
Two Sigma Securities LLC has acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the second quarter, purchasing 11,311 shares valued at approximately $1.02 million. HealthEquity reported strong quarterly results, exceeding analyst expectations with $1.24 EPS and a 95.5% year-over-year revenue increase, leading to a "Moderate Buy" consensus rating from analysts. Institutional investors hold a significant 99.55% of the company's stock, despite recent insider share sales.
Grandeur Peak Global Advisors LLC Sells 31,570 Shares of HealthEquity, Inc. $HQY
Grandeur Peak Global Advisors LLC significantly reduced its stake in HealthEquity, Inc. (NASDAQ:HQY) by selling 31,570 shares, retaining 4,875 shares valued at approximately $440,000. Despite this, institutional investors still hold 99.55% of the company, and HealthEquity reported strong Q2 results, exceeding revenue and EPS expectations and raising fiscal 2027 guidance. Analysts maintain a "Moderate Buy" rating with a target price of $110.93, although some insider selling was recently noted.
80,893 Shares in HealthEquity, Inc. $HQY Acquired by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company recently acquired 80,893 shares of HealthEquity, Inc. (NASDAQ:HQY) valued at approximately $7.3 million, contributing to the 99.55% institutional ownership of the stock. HealthEquity exceeded Q2 expectations with adjusted EPS of $1.24 and revenue of $350.7 million, leading management to raise fiscal 2027 adjusted EPS guidance. Despite a "Moderate Buy" consensus from analysts, the stock trades at a premium valuation and saw insider sales totaling $1.26 million last quarter.
Canada Pension Plan Investment Board Makes New Investment in HealthEquity, Inc. $HQY
The Canada Pension Plan Investment Board recently acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY), purchasing 135,600 shares valued at approximately $12.25 million. This investment comes as HealthEquity reported strong Q2 earnings, exceeding analyst expectations with EPS of $1.24 and revenue up 95.5% year-over-year. Despite positive analyst ratings and raised fiscal 2027 guidance, the stock trades at a premium valuation, and some insiders have recently sold shares.
EFG International AG Acquires New Position in HealthEquity, Inc. $HQY
EFG International AG has acquired a new stake of 41,028 shares, valued at approximately $3.7 million, in HealthEquity, Inc. during the second quarter. HealthEquity has received a consensus "Moderate Buy" rating from analysts with an average price target of $110.93, following strong Q2 earnings that beat expectations. Other institutional investors like BlackRock Inc. and Wasatch Advisors LP also made significant moves in their HealthEquity holdings, while some insiders sold shares.
HealthEquity (NASDAQ: HQY) director plans $804K stock sale
HealthEquity director Adrian Dillon plans to sell 7,632 shares of common stock, valued at approximately $804,412.80, through Morgan Stanley Smith Barney LLC. The shares are to be acquired via exercise of stock options and sold on NASDAQ around August 25, 2026, as detailed in a Rule 144 SEC filing. This transaction indicates a substantial insider sale by a company director.
Ieq Capital LLC Purchases Shares of 31,528 HealthEquity, Inc. $HQY
Ieq Capital LLC has acquired 31,528 shares of HealthEquity, Inc. (NASDAQ:HQY) for approximately $2.85 million in the second quarter, making it one of several institutional investors to increase holdings in the company. Analysts have a "Moderate Buy" consensus rating for HealthEquity with an average price target of $110.93, following strong Q1 earnings where EPS exceeded estimates and revenue grew by 7.2% year-over-year. Despite insider selling activity totaling $1.65 million over 90 days, institutional ownership stands at 99.55%.
Wells Fargo Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $125
Wells Fargo has reiterated its Buy rating for HealthEquity (HQY.US) and maintained its price target of $125. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Ahead of HealthEquity (HQY) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
HealthEquity (HQY) is projected to report Q2 earnings of $1.19 per share, a 10.2% year-over-year increase, with revenues anticipated to reach $350.23 million, up 7.5%. Analysts have maintained their EPS estimates for the quarter. Key metric forecasts include an increase in 'Revenue- Service' to $121.10 million, 'Revenue- Custodial' to $177.70 million, and 'Total HSA Assets' to $37.64 billion.
Ranger Investment Management L.P. Purchases Shares of 319,253 HealthEquity, Inc. $HQY
Ranger Investment Management L.P. acquired a new stake of 319,253 shares in HealthEquity, Inc. (NASDAQ:HQY) during the second quarter, valued at approximately $28.8 million, making it their 16th largest holding. Institutional investors collectively own 99.55% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $110.93. HealthEquity recently surpassed earnings expectations with an adjusted EPS of $1.24 and revenue of $354.64 million, while insider selling by executives also occurred.
Deutsche Bank AG Makes New $11.99 Million Investment in HealthEquity, Inc. $HQY
Deutsche Bank AG has acquired a new position in HealthEquity, Inc. (NASDAQ:HQY), investing approximately $11.99 million by purchasing 132,705 shares. This move makes Deutsche Bank AG a 0.16% owner of HealthEquity, as other institutional investors also adjusted their holdings in the company. HealthEquity's stock recently traded up 1.1%, with insights into its financial performance, insider transactions, and analyst ratings also detailed.
Earnings Preview: HealthEquity to Report Financial Results Pre-market on August 27
HealthEquity (HQY.US) is set to release its Q2 2027 financial results pre-market on August 27 ET. Analysts project revenue of $349.23 million, an increase of 7.18% year-over-year, and an EPS of $0.756, up 11.13% year-over-year. The company typically hosts a conference call to discuss these results and engage with investors.
William Blair Investment Management LLC Acquires New Stake in HealthEquity, Inc. $HQY
William Blair Investment Management LLC has acquired a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the second quarter, purchasing 1.77 million shares valued at approximately $160.2 million. This investment gives William Blair a 2.12% stake in the company, which is 99.55% institutionally owned. HealthEquity recently exceeded quarterly earnings and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $110.93.
Sumitomo Life Insurance Co. Buys Shares of 17,142 HealthEquity, Inc. $HQY
Sumitomo Life Insurance Co. has initiated a new position in HealthEquity, Inc. (NASDAQ:HQY), purchasing 17,142 shares valued at approximately $1.55 million in the second quarter. HealthEquity reported strong quarterly earnings, exceeding analyst expectations with $1.24 EPS and $354.64 million in revenue. Despite some insider selling totaling $1.65 million over the past 90 days, analysts maintain a "Moderate Buy" consensus rating with an average target price of $110.93 for the stock.
BlackRock Inc. Takes $1.02 Billion Position in HealthEquity, Inc. $HQY
BlackRock Inc. has acquired a significant position in HealthEquity, Inc. (NASDAQ:HQY), purchasing over 11.2 million shares valued at approximately $1.02 billion, giving it a 13.49% stake. This move by BlackRock comes as other institutional investors have also adjusted their holdings in HealthEquity, which maintains a "Moderate Buy" consensus rating from analysts with an average price target of $110.93. The company recently surpassed quarterly earnings expectations, reporting $1.24 EPS against an expected $1.11, and saw a 7.2% year-over-year revenue increase to $354.64 million.
Paralel Advisors LLC Takes $2.50 Million Position in HealthEquity, Inc. $HQY
Paralel Advisors LLC has acquired a new position in HealthEquity, Inc. (NASDAQ:HQY) during the second quarter, purchasing 27,661 shares valued at approximately $2.50 million. HealthEquity has shown strong performance, exceeding quarterly earnings expectations with $1.24 EPS and $354.64 million in revenue, leading to a consensus "Moderate Buy" rating from analysts with an average price target of $110.93. Despite some insider selling, institutional investors hold 99.55% of the company's stock, reflecting strong confidence in its financial health and future guidance.
B. Metzler seel. Sohn & Co. AG Makes New $10.04 Million Investment in HealthEquity, Inc. $HQY
B. Metzler seel. Sohn & Co. AG has made a new investment of $10.04 million in HealthEquity, Inc. (NASDAQ:HQY) by purchasing 111,108 shares. This makes them owners of 0.13% of the company, which is also significantly held by other institutional investors and hedge funds (99.55%). The article details HealthEquity's financial performance, analyst ratings, and recent insider transactions.
HealthEquity (HQY) Expected to Announce Earnings on Thursday
HealthEquity (HQY) is anticipated to release its Q2 fiscal 2027 earnings after market close on Thursday, August 27th. Analysts project earnings of $1.19 per share on revenue of $349.2 million, with the company's full-year EPS guidance set between $2.88 and $2.95. The company surpassed expectations in its previous quarter, reporting $1.24 EPS against a $1.11 consensus and revenue of $354.6 million, an increase of 7.2% year-over-year.
Summit Creek Advisors LLC Makes New $7.60 Million Investment in HealthEquity, Inc. $HQY
Summit Creek Advisors LLC has made a new $7.60 million investment in HealthEquity, Inc. (NASDAQ:HQY), purchasing 84,157 shares and making it their ninth-largest holding. HealthEquity reported strong quarterly earnings, beating analyst estimates with EPS of $1.24 and a 7.2% year-over-year revenue increase. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $110.93.
Diversify Advisory Services LLC Invests $8.98 Million in HealthEquity, Inc. $HQY
Diversify Advisory Services LLC has purchased a new position in HealthEquity, Inc. (NASDAQ:HQY) worth approximately $8.98 million, acquiring 90,675 shares. This investment makes Diversify Advisory Services LLC the owner of about 0.11% of HealthEquity. The article also details recent insider stock sales and analyst ratings, with HealthEquity currently holding a "Moderate Buy" consensus rating and an average target price of $110.93.
KeyBanc Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $125
KeyBanc has reiterated its Buy rating on HealthEquity (HQY.US) and maintained its price target of $125. This indicates continued confidence in the company's performance and future prospects from the analyst firm.
HQY5271388 Bond Risk Profile
This page provides a risk profile for the HealthEquity, Inc. 4.5% 01-OCT-2029 bond, identified as HQY5271388. It offers an overview of the bond's coupon, redemption, and risks, with a focus on credit risk assessment. The platform gathers key metrics like security level, inflation protection, and issuer rating to help evaluate the bond's reliability.
Maridea Wealth Management LLC Makes New $2.75 Million Investment in HealthEquity, Inc. $HQY
Maridea Wealth Management LLC has made a new $2.75 million investment in HealthEquity, Inc., acquiring 30,479 shares during the second quarter. HealthEquity recently reported strong quarterly earnings of $1.24 per share, surpassing estimates, and saw its revenue increase by 7.2% year over year. Analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $110.93.
Oppenheimer Asset Management Inc. Makes New $21.08 Million Investment in HealthEquity, Inc. $HQY
Oppenheimer Asset Management Inc. has initiated a significant new investment in HealthEquity, Inc. (NASDAQ:HQY), acquiring 233,378 shares valued at approximately $21.08 million. This investment comes as HealthEquity reported strong quarterly earnings, beating analyst estimates with $1.24 per share and a 7.2% revenue increase. The company maintains a "Moderate Buy" rating from analysts with an average price target of $110.93, despite some recent insider stock sales.
Assenagon Asset Management S.A. Makes New Investment in HealthEquity, Inc. $HQY
Assenagon Asset Management S.A. has initiated a new position in HealthEquity, Inc. (NASDAQ:HQY) by purchasing 21,215 shares valued at approximately $1.9 million. This investment comes as HealthEquity exceeded its quarterly earnings expectations with $1.24 EPS and revenue of $354.64 million, representing a 7.2% year-over-year increase. Analysts maintain a "Moderate Buy" rating for HQY with an average price target of $110.93, despite recent insider share sales totaling $1.65 million.
Wasatch Advisors LP Has $719.01 Million Holdings in HealthEquity, Inc. $HQY
Wasatch Advisors LP significantly increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 10.5% in the second quarter, bringing its total holdings to 7.96 million shares valued at $719.01 million. This makes HealthEquity the largest holding for Wasatch, representing 9.52% of the company and 4.7% of Wasatch's portfolio. HealthEquity recently reported strong quarterly earnings, beating analyst estimates with $1.24 per share and a 7.2% revenue increase, leading to a "Moderate Buy" consensus rating from analysts with a $110.93 price target.
Technical Reactions to HQY Trends in Macro Strategies
This article provides a technical analysis of Healthequity Inc. (NYSE: HQY), highlighting strong near and mid-term sentiment, potential for long-term extension, and compelling upside due to no resistance above the current price. It outlines three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis for support and resistance levels.
HealthEquity (NASDAQ:HQY) Hits New 52-Week High - Here's What Happened
HealthEquity (NASDAQ:HQY) recently reached a new 52-week high, trading up to $107.62, following a strong earnings report where adjusted EPS of $1.24 beat estimates by $0.13, and revenue increased 7.2% year-over-year. Analysts maintain a "Moderate Buy" rating with an average price target of $110.93, despite recent insider stock sales totaling $1.65 million. The company's financial health is further indicated by its revenue growth and positive analyst sentiment.
HealthEquity, Inc. (HQY) Stock Analysis: Investor Optimism With 13% Upside Potential
HealthEquity, Inc. (HQY) is attracting investor attention with its robust service offerings in health information services, specializing in HSAs, FSAs, and other health-related financial services. Currently trading near its 52-week high at $104.63, analysts project a 13.29% upside potential with a consensus target price of $118.53, driven by positive sentiment and strong financial indicators like a 7.20% revenue growth and $370 million in free cash flow. The company maintains an overwhelmingly positive outlook from analysts with 15 buy ratings and no hold or sell recommendations, positioning it as a compelling growth-oriented investment in the healthcare sector.
Is HealthEquity (HQY) Stock Rich Or Reasonable Today?
HealthEquity (HQY) stock shows conflicting valuation signals; while a Discounted Cash Flow (DCF) model suggests it's undervalued by nearly 40%, its P/E ratio indicates it's overvalued compared to its tailored fair multiple and the broader healthcare sector. The company's 61.0% return over the past five years raises questions about its current valuation, with overall checks not deeming it a clear bargain. Investors must consider whether its cash flow generation can justify a higher intrinsic value or if market multiples will cap its price.
Bank of America Corp DE Purchases 261,150 Shares of HealthEquity, Inc. $HQY
Bank of America Corp DE significantly increased its stake in HealthEquity, Inc. by 43.5% in the first quarter, purchasing 261,150 additional shares, bringing its total holdings to 862,008 shares valued at approximately $72 million. Institutional investors now collectively own 99.55% of HQY, with several other major funds also raising their positions. Analysts maintain a "Moderate Buy" rating for HealthEquity, with an average price target of $110.93, following the company's strong first-quarter earnings that surpassed expectations.
Quantinno Capital Management LP Purchases 30,797 Shares of HealthEquity, Inc. $HQY
Quantinno Capital Management LP significantly increased its stake in HealthEquity, Inc. (NASDAQ:HQY) during the first quarter, adding 30,797 shares to bring its total holding to 44,162 shares valued at approximately $3.69 million. This move comes as HealthEquity reported strong financial results, beating analyst estimates for EPS and revenue, and provided positive fiscal 2027 guidance. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $110.93.
HealthEquity, Inc. $HQY Stake Boosted by Beacon Investment Advisory Services Inc.
Beacon Investment Advisory Services Inc. significantly increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 63.4% in the second quarter, bringing its total holdings to 94,237 shares valued at approximately $8.5 million. This boost follows HealthEquity's strong financial performance, exceeding quarterly expectations with $1.24 EPS and $354.64 million in revenue, alongside positive fiscal 2027 guidance. Analyst sentiment remains favorable with a "Moderate Buy" rating and an average price target of $110.93, despite recent insider stock sales.
Healthequity Inc (HQY) Stock News Today
This article provides current stock information for Healthequity Inc (HQY), including its market cap, P/E ratio, and recent stock performance. It notes that more news, earnings, and analyst ratings for HQY are expected soon. The page serves as a hub for investors to follow developments related to the company's stock.
Healthequity Inc (HQY) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Healthequity Inc (HQY), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that 16 analysts rate HQY with a "Buy" trend, projecting an average price target of $123.50. The piece also includes expected revenue and EPS for upcoming quarters and compares HQY's analyst coverage with peers in the Software & IT Services industry.
Healthequity Inc stock hits 52-week high at 106.42 USD By Investing.com
HealthEquity Inc (HQY) stock has reached a new 52-week high of $106.42, with a market capitalization of $8.78 billion. The company's stock has seen significant growth, with a 15.42% increase over the past year and a 32.5% return in the last six months, driven by strong financial results and strategic initiatives. Analysts maintain a positive outlook, with upgraded ratings and price targets, indicating continued confidence in HealthEquity's growth and margin potential.
Healthequity Inc stock hits 52-week high at 106.42 USD
Healthequity Inc (HQY) stock has reached a 52-week high of $106.42, demonstrating a 15.42% positive change over the past year and a 32.5% return in the last six months. The company recently reported strong Q1 fiscal year 2027 financial results, exceeding market expectations for EPS and revenue, while Moody’s upgraded its corporate family rating. Several analysts, including RBC Capital and Citizens, have reiterated or raised their price targets, indicating a positive outlook for the company's growth and margin potential.
Healthequity Inc stock hits 52-week high at 106.42 USD By Investing.com
Healthequity Inc (HQY) stock reached a new 52-week high of $106.42, demonstrating a 15.42% positive change over the past year and a 32.5% return in the last six months. This surge follows strong Q1 fiscal year 2027 results, surpassing market expectations for EPS and revenue, and a Moody's Ratings upgrade to Ba2. RBC Capital and Citizens have reiterated Outperform ratings with increased price targets, reflecting confidence in the company's growth and financial momentum.
California State Teachers Retirement System Has $8.41 Million Holdings in HealthEquity, Inc. $HQY
The California State Teachers Retirement System increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 23.7% in the first quarter, now holding 100,604 shares valued at $8.41 million. Other institutional investors have also adjusted their positions, and analysts have largely issued "Buy" or "Outperform" ratings for the stock. Insider selling has also occurred, with executives selling shares worth over $1.6 million in the last 90 days.
HealthEquity, Inc. $HQY Shares Sold by Royal Bank of Canada
Royal Bank of Canada reduced its stake in HealthEquity, Inc. (NASDAQ:HQY) by 11.7% in the first quarter, selling 39,458 shares and retaining 299,007 shares valued at approximately $25.0 million. HealthEquity reported strong quarterly earnings of $1.24 per share, surpassing estimates, with revenue increasing 7.2% year over year. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and a target price of $110.93 for the stock.
HealthEquity Lists Three September Investor Conference Dates
HealthEquity (NASDAQ: HQY) announced its Q2 fiscal 2027 earnings release for August 27, 2026, followed by an investor conference call. Additionally, the company's management plans to present and meet with investors at three healthcare conferences in September 2026: the Wells Fargo Healthcare Conference, the Baird Global Healthcare Conference, and the Deutsche Bank Healthcare Summit. The press release provides details for accessing the earnings call and the dates and locations for the upcoming investor conferences.
